ReviewGynecologic oncology reports2026
The role of ovarian transposition prior to pelvic radiation: A review.
Review in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This review aims to summarize the indications, surgical techniques, and outcomes of ovarian transposition (OT) prior to pelvic radiation for cancers in the pelvis to inform providers for patient counseling and candidate selection. Methods: We reviewed published literature to identify studies reporting on OT indications, techniques, complications, ovarian function outcomes, and fertility outcomes. Systematic reviews, Results: Reported success rates for preservation of ovarian function following OT vary (15-100%) depending on the type of cancer, radiation dosing, location of transposed ovaries, use of adjuvant chemotherapy, and individual patient factors. Approximately 50-65% of patients with cervical cancer who undergo OT followed by external beam radiation therapy with or without brachytherapy maintain ovarian function; adjuvant chemotherapy further reduces ovarian function preservation. Ovarian function is more likely to be preserved the further ovaries are transposed from the radiation field. The location of transposed ovaries should be at least 4 cm from the radiation field or 1.5 cm above the iliac crest to avoid gonadotoxic radiation doses. Perioperative complications are uncommon, and the risk of ovarian metastasis is very low (0.36%) in appropriately selected patients. Conclusion: Maintaining ovarian function helps prevent radiation-induced primary ovarian insufficiency and its associated morbidities, enables avoidance of hormone replacement therapy, and preserves certain fertility options. OT should be offered to pre-menopausal women aged 40 or younger without elevated ovarian metastasis risk who are planned to receive pelvic radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.